1. Home
  2. ZSTK vs LEXX Comparison

ZSTK vs LEXX Comparison

Compare ZSTK & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ZSTK

ZeroStack Corp. Common Stock

N/A

Current Price

$5.30

Market Cap

20.0M

Sector

Health Care

ML Signal

N/A

Logo Lexaria Bioscience Corp.

LEXX

Lexaria Bioscience Corp.

HOLD

Current Price

$0.71

Market Cap

16.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZSTK
LEXX
Founded
2019
2004
Country
Canada
Canada
Employees
76
7
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
20.0M
16.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ZSTK
LEXX
Price
$5.30
$0.71
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$1.50
AVG Volume (30 Days)
8.8K
221.1K
Earning Date
05-12-2026
04-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$15.73
N/A
Revenue Next Year
N/A
$601.47
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.76
$0.46
52 Week High
$11.00
$1.55

Technical Indicators

Market Signals
Indicator
ZSTK
LEXX
Relative Strength Index (RSI) 37.54 38.72
Support Level $4.76 $0.62
Resistance Level $9.65 $0.85
Average True Range (ATR) 0.69 0.10
MACD -0.07 -0.04
Stochastic Oscillator 0.84 34.79

Price Performance

Historical Comparison
ZSTK
LEXX

About ZSTK ZeroStack Corp. Common Stock

ZeroStack Corp is an AI focused asset management company. The company also operates a world-wide pharmaceutical distribution business through its wholly owned subsidiary. ZeroStack is focused on providing exposure to decentralized AI through a concentrated digital asset approach structured to generate yield and fee-based income from staking validators, compute power technology companies, and complementary businesses within the ecosystem and across the wider AI landscape.

About LEXX Lexaria Bioscience Corp.

Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.

Share on Social Networks: